Citadel Advisors - AKARI THERAPEUTICS PLC ownership

AKARI THERAPEUTICS PLC's ticker is AKTX and the CUSIP is 00972G108. A total of 15 filers reported holding AKARI THERAPEUTICS PLC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of AKARI THERAPEUTICS PLC
ValueSharesWeighting
Q4 2022$7,569
-49.5%
15,446
+2.5%
0.00%
Q2 2022$15,000
-75.8%
15,064
-60.1%
0.00%
Q3 2021$62,000
-31.1%
37,770
-27.7%
0.00%
Q2 2021$90,000
+23.3%
52,265
+88.6%
0.00%
Q1 2021$73,000
+78.0%
27,712
+46.2%
0.00%
Q2 2020$41,00018,9570.00%
Other shareholders
AKARI THERAPEUTICS PLC shareholders Q3 2022
NameSharesValueWeighting ↓
VHCP Management II, LLC 426,297$2,617,0000.72%
Vivo Capital, LLC 345,850$2,124,0000.43%
Hikari Power Ltd 151,334$929,0000.12%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 433,551$2,662,0000.12%
NEA Management Company, LLC 452,167$2,776,0000.10%
Baker Brothers Advisors 496,901$3,051,0000.02%
HUNTINGTON NATIONAL BANK 8,000$49,0000.00%
MILLENNIUM MANAGEMENT LLC 115,543$709,0000.00%
DEUTSCHE BANK AG\ 5,300$32,0000.00%
MORGAN STANLEY 8,807$54,0000.00%
View complete list of AKARI THERAPEUTICS PLC shareholders